H1B Salary Data

Home › Employers › GeneFab, LLC

GeneFab, LLC: H-1B salaries and sponsorship

GeneFab, LLC filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 2. Median offered salary: $112,464.

Applications (LCAs)3
Certified2
Employer addressAlameda, CA
H-1B dependent employerNo
Median offered salary$112,464
Middle half of salaries$111,196–$113,732
10th–90th percentile$110,435–$114,493

Does GeneFab, LLC sponsor H-1B visas?

GeneFab, LLC filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Jun 5, 2024. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Sr Research Associate II, Viral Vector Process Development2$109,928
Scientist 2, Analytical Development1$115,000

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20243$112,464

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Scientist 2, Analytical Development$115,000–$160,000
Level II
Alameda, CAJun 5, 2024Jun 10, 2024Certified
Sr Research Associate II, Viral Vector Process Development$109,928–$130,000
Level II
Alameda, CAJan 2, 2024Jan 15, 2024Certified
Sr Research Associate II, Viral Vector Process Development$109,928–$130,000
Level II
Alameda, CADec 19, 2023Jan 15, 2024Withdrawn

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).